Home›Trial›NCT06154252
🔬NCT06154252Phase 2Phase 3RECRUITING

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

Study Summary

RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

Conditions
Idiopathic Inflammatory MyopathyDermatomyositisAnti-Synthetase SyndromeImmune-Mediated Necrotizing MyopathyJuvenile DermatomyositisJuvenile PolymyositisJuvenile Idiopathic Inflammatory Myopathy (JIIM)Juvenile Myositis
Interventions / Drugs
CABA-201 following preconditioning with fludarabine and cyclophosphamide
View on ClinicalTrials.gov ↗
Sponsor
CABA
Cabaletta Bio
Immunology
D48/100
Study Details
Enrollment74 participants
Primary Completion—
Lead SponsorCabaletta Bio
Data Retrieved2026-04-11 04:08:39.574160+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.